These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 24807266)

  • 21. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
    Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
    Wang J; Zhang Y; Zu Y; Li Z; Li M; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):110-4. PubMed ID: 27014979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
    O'Hare T; Shakespeare WC; Zhu X; Eide CA; Rivera VM; Wang F; Adrian LT; Zhou T; Huang WS; Xu Q; Metcalf CA; Tyner JW; Loriaux MM; Corbin AS; Wardwell S; Ning Y; Keats JA; Wang Y; Sundaramoorthi R; Thomas M; Zhou D; Snodgrass J; Commodore L; Sawyer TK; Dalgarno DC; Deininger MW; Druker BJ; Clackson T
    Cancer Cell; 2009 Nov; 16(5):401-12. PubMed ID: 19878872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a Candidate Containing an (
    Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H
    J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
    Wehrle J; von Bubnoff N
    Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
    O'Hare T; Deininger MW; Eide CA; Clackson T; Druker BJ
    Clin Cancer Res; 2011 Jan; 17(2):212-21. PubMed ID: 21098337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
    Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ponatinib: a third-generation inhibitor for the treatment of CML.
    Wehrle J; Pahl HL; von Bubnoff N
    Recent Results Cancer Res; 2014; 201():99-107. PubMed ID: 24756787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
    Frankfurt O; Licht JD
    Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
    Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
    Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
    Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
    Haddad FG; Sasaki K; Nasr L; Short NJ; Kadia T; Dellasala S; Cortes J; Nicolini FE; Issa GC; Jabbour E; Kantarjian H
    Cancer; 2024 Oct; 130(19):3344-3352. PubMed ID: 38804723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.